FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC By Ogkologos - August 5, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASCENT-03 and ASCENT-04/KEYNOTE D-19 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Reunión anual de la American Society of Clinical Oncology de 2023:... June 3, 2023 Fatiga relacionada con el cáncer: Lo que las personas con cáncer... March 2, 2021 Genetic Signature May Help Tailor Treatment for Meningioma December 21, 2023 How to Be Brave When Your Parent Has Cancer: A Kid’s... April 13, 2021 Load more HOT NEWS Male Patients with Cancer at Higher Risk of Severe Disease Course... 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord... Cancer Rehabilitation Starts at Diagnosis: Part II FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic...
